| __timestamp | AstraZeneca PLC | Lantheus Holdings, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 13324000000 | 72429000 |
| Thursday, January 1, 2015 | 11451000000 | 78634000 |
| Friday, January 1, 2016 | 9739000000 | 75374000 |
| Sunday, January 1, 2017 | 10543000000 | 92157000 |
| Monday, January 1, 2018 | 10362000000 | 93326000 |
| Tuesday, January 1, 2019 | 11848000000 | 103132000 |
| Wednesday, January 1, 2020 | 11693000000 | 110171000 |
| Friday, January 1, 2021 | 15680000000 | 218817000 |
| Saturday, January 1, 2022 | 18955000000 | 233827000 |
| Sunday, January 1, 2023 | 18025000000 | 267194000 |
| Monday, January 1, 2024 | 20532000000 |
Unveiling the hidden dimensions of data
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, AstraZeneca PLC and Lantheus Holdings, Inc. have demonstrated contrasting approaches to SG&A cost management. From 2014 to 2023, AstraZeneca's SG&A expenses have fluctuated, peaking in 2022 with a 42% increase from 2016. In contrast, Lantheus Holdings, Inc. has maintained a more consistent and controlled SG&A trajectory, with expenses rising by approximately 270% over the same period. This stark difference highlights AstraZeneca's expansive strategy versus Lantheus's more conservative approach. As the industry evolves, these strategies will play a pivotal role in shaping each company's financial health and market position. Investors and analysts should closely monitor these trends to gauge future performance and strategic direction.
Cost Management Insights: SG&A Expenses for AstraZeneca PLC and argenx SE
Who Optimizes SG&A Costs Better? AstraZeneca PLC or Gilead Sciences, Inc.
Selling, General, and Administrative Costs: AstraZeneca PLC vs Axsome Therapeutics, Inc.
AstraZeneca PLC vs Catalyst Pharmaceuticals, Inc.: SG&A Expense Trends
AstraZeneca PLC vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
AstraZeneca PLC and Taro Pharmaceutical Industries Ltd.: SG&A Spending Patterns Compared
Regeneron Pharmaceuticals, Inc. vs Lantheus Holdings, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Lantheus Holdings, Inc.
Lantheus Holdings, Inc. or Ultragenyx Pharmaceutical Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Lantheus Holdings, Inc. and Merus N.V.
Cost Management Insights: SG&A Expenses for Lantheus Holdings, Inc. and Galapagos NV
Lantheus Holdings, Inc. and Travere Therapeutics, Inc.: SG&A Spending Patterns Compared